GoodRx Offers 60% Discount on Repatha, Making Cholesterol-Lowering Therapy More Affordable for Patients Nationwide

GoodRx has expanded access to Repatha, a cholesterol-lowering therapy, with nearly 60% savings. Patients can now access Repatha for $239 at over 70,000 pharmacies nationwide. The platform is helping bypass traditional insurance hurdles and making the therapy more accessible to patients. GoodRx's direct-to-consumer solutions give brands a trusted channel to deliver real savings to patients.

GoodRx, the leading platform for medication savings in the U.S., has announced a significant reduction in the cash price of Repatha (evolocumab), a cholesterol-lowering therapy. Starting today, patients can access Repatha for $239 at over 70,000 pharmacies nationwide, representing a nearly 60% savings off the retail pharmacy list price GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings^[1].

The initiative, which aims to make innovative therapies more accessible, is a collaboration between GoodRx and Amgen. By offering Repatha at a reduced cash price, GoodRx and Amgen are helping patients bypass traditional insurance hurdles such as restrictive formularies and high deductibles. This move is part of GoodRx's ongoing effort to provide meaningful savings to patients at scale GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings^[1].

Laura Jensen, Chief Commercial Officer and President of Pharma Solutions at GoodRx, highlighted the importance of this partnership. "In a healthcare system where affordability too often dictates access, GoodRx remains focused on delivering meaningful savings to patients at scale," she said. "GoodRx is serving as the digital storefront to make Repatha more accessible for patients, leveraging our extensive retail pharmacy network to ensure it’s available where they already fill their prescriptions" GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings^[1].

Amgen has also launched a direct-to-patient program called AmgenNow, offering Repatha at a $239 monthly price, nearly 60% below the current U.S. list price. The program is open to all patients, including uninsured individuals, high-deductible plan holders, cash payers, and participants in Medicare and Medicaid AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.^[2].

The $239 price point is the lowest among G-7 countries and is part of Amgen's strategy to expand access to Repatha. The company cites the VESALIUS-CV Phase 3 results, which showed reduced major adverse cardiovascular events in patients using Repatha AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.^[2].

The impact of these initiatives remains to be seen, as benefits depend on real-world uptake, patient eligibility, and payer reactions. Investors and financial professionals should monitor monthly enrollment figures, any payer policy changes, and how the company reports uptake over the next 6–12 months AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.^[2].